Mizuho MedyMIZUHO MEDY CO.,LTD.4595東証スタンダード医薬品FY ending Dec 2025, non-consolidated, J-GAAP
Out of every ¥100 of sales, about ¥41 is left as operating profit. Revenue changed -1.5% from the prior year, operating profit -5.5%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2021 | 36.7% | 1.08× | 39.5% | 1.52× | 60.0% |
| 2022 | 44.6% | 1.12× | 50.1% | 1.40× | 70.3% |
| 2023 | 34.3% | 0.58× | 19.8% | 1.27× | 25.2% |
| 2024 | 33.0% | 0.58× | 19.0% | 1.20× | 22.8% |
| 2025 | 30.4% | 0.52× | 15.9% | 1.20× | 19.0% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 13,137 | 17,582 | 10,989 | 11,429 | 11,260 |
| Cost of revenue | 3,234 | 3,482 | 2,915 | 3,346 | 3,441 |
| Gross profit | 9,903 | 14,100 | 8,074 | 8,083 | 7,819 |
| SG&A | 2,954 | 2,996 | 2,922 | 3,166 | 3,172 |
| Operating income | 6,698 | 11,104 | 5,151 | 4,917 | 4,646 |
| Pretax income | 6,825 | 11,071 | 5,292 | 5,167 | 4,736 |
| Income tax | 2,008 | 3,233 | 1,518 | 1,393 | 1,310 |
| Net income attributable to owners | 4,817 | 7,838 | 3,774 | 3,773 | 3,425 |
| Operating margin | 51.0% | 63.2% | 46.9% | 43.0% | 41.3% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥4.33B | ¥7.38B | ¥8.72B | ¥9.66B | ¥2.26B |
| Total assets | ¥12.2B | ¥19.1B | ¥18.9B | ¥20.7B | ¥22.4B |
| Net assets | ¥8.03B | ¥14.3B | ¥15.7B | ¥17.4B | ¥18.7B |
| Share capital | ¥464.5M | ¥464.5M | ¥464M | ¥464M | ¥464M |
| Property, plant and equipment | ¥2.1B | ¥2.15B | ¥2.25B | ¥2.27B | ¥2.26B |
| Intangible assets excluding goodwill | ¥12.2M | ¥14.3M | ¥11M | ¥10M | ¥36M |
| Investment securities | ¥7.8M | ¥7.9M | ¥8M | ¥8M | ¥3M |
| Current assets | ¥9.66B | ¥16.5B | ¥16.3B | ¥18B | ¥19.6B |
| Current liabilities | ¥3.34B | ¥3.92B | ¥2.28B | ¥2.29B | ¥2.66B |
| Total liabilities | ¥4.16B | ¥4.82B | ¥3.27B | ¥3.38B | ¥3.69B |
| Equity attributable to owners of parent | ¥8.03B | ¥14.3B | ¥15.7B | ¥17.4B | ¥18.7B |
| Retained earnings | ¥7.29B | ¥13.5B | ¥14.9B | ¥16.6B | ¥17.9B |
| Treasury stock | -¥1.8M | -¥1.9M | -¥2M | -¥2M | -¥2M |
EDINET (FSA Japan)
有価証券報告書－第49期(2025/01/01－2025/12/31)
EDINET (FSA Japan)
有価証券報告書－第48期(2024/01/01－2024/12/31)
EDINET (FSA Japan)
有価証券報告書－第47期(2023/01/01－2023/12/31)
EDINET (FSA Japan)
有価証券報告書－第46期(2022/01/01－2022/12/31)
EDINET (FSA Japan)
有価証券報告書－第45期(令和3年1月1日－令和3年12月31日)
EDINET (FSA Japan)
有価証券報告書－第44期(令和2年1月1日－令和2年12月31日)
Extracted from XBRL: 44 / Derived from other figures: 2
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.